Compass Therapeutics, Inc.?s CEO succession plan is effective as of January 9, 2024, with the elevation of Vered Bisker-Leib, PhD, to Chief Executive Officer and her addition to the Compass board of directors. Thomas Schuetz, MD, PhD, Compass? Scientific Founder and current Chief Executive Officer will transition to President of Research and Development and assume the role of Vice Chair of the Compass board of directors.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
1.6 USD | +3.90% | +0.63% | +2.56% |
13/05 | Compass Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
06/05 | Top Premarket Gainers | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+2.56% | 212M | |
+7.63% | 113B | |
+10.39% | 106B | |
+0.41% | 22.27B | |
-11.89% | 22.22B | |
-5.99% | 19.43B | |
-37.36% | 17.87B | |
-5.25% | 17.24B | |
+6.54% | 14.29B | |
+36.09% | 12.52B |
- Stock Market
- Equities
- CMPX Stock
- News Compass Therapeutics, Inc.
- Compass Therapeutics, Inc. Announces Executive Changes, Effective January 9, 2024